Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

CVS Group Shares: Is Australian Expansion Becoming a Bigger Growth Engine? (LSE:CVSG)

Why is CVS Group PLC in focus today?As of 16 October 2026, the case for following CVS Group PLC is linked to the company’s latest reported operating picture and the wider market conditions affecting veterinary healthcare services. The wider UK equity market has been …

Ankur Sharma | 16 October 2026

Solvonis Therapeutics (LSE:SVNS): London Stock Exchange Main Market Investors Watch Holdings in Company as October Market Focus Builds

Solvonis Therapeutics (LSE:SVNS) appears in the 16 October 2026 market announcement feed under “Holdings in Company”. The announcement subject, rather than a verified same-day price move, provides the immediate news hook. Investors should distinguish disclosed facts from possible implications.

Ankur Sharma | 16 October 2026

What CVS Group's results and buyback reveal about the FTSE 250 veterinary group

CVS Group (LSE:CVSG), the FTSE 250 veterinary services provider, has spent the weeks since its 24 September full-year results buying back shares while setting out an outlook for growth after a period shaped by the Competition and Markets Authority (CMA) investigation into the veterinary …

Divya Sood | 16 October 2026

What Oxford Biomedica's record client wins mean for this FTSE 250 cell and gene therapy manufacturer (LSE:OXB)

Oxford Biomedica (LSE:OXB), the viral vector contract development and manufacturing organisation known as OXB, has spent the weeks since its 22 September interim results setting out how it plans to turn a fast-growing order book into profit. The half-year statement covering the six months …

Ishan Mudgal | 16 October 2026

How Oxford Nanopore Is Narrowing Losses as It Seeks to Regain FTSE 250 Favour (LSE:ONT)

Oxford Nanopore Technologies (LSE:ONT), the Oxford-based developer of DNA and RNA sequencing platforms, has spent much of 2026 trying to rebuild investor confidence after a bumpy period for its shares. Its interim results for the six months to 30 June, published on 19 August, …

Ishan Mudgal | 16 October 2026

How Hikma Pharmaceuticals Is Leaning on Its Branded Business to Hold Its FTSE 250 Ground (LSE:HIK)

Hikma Pharmaceuticals Plc (LSE:HIK), the London-listed generic and specialty drugmaker, has kept investors focused on execution in 2026, with management emphasising steady delivery across its injectables, branded and generics operations. Its interim results, published on 6 August 2026, showed modest top-line growth, firmer profitability …

Ishan Mudgal | 16 October 2026

Why Genus Remains in Focus on the FTSE 250 After a Solid Year and a £60m Buyback

Genus plc (LSE:GNS), the animal genetics specialist behind the PIC pig breeding and ABS bovine businesses, has given investors plenty to consider in recent weeks. Its preliminary results for the year ended 30 June 2026, released on 10 September, showed sharply higher profits, a …

Divya Sood | 16 October 2026

Halma Shares Under Pressure: Can Its Defensive Growth Credentials Win Investors Back? (HLMA)

Halma is in focus as investors reassess quality-growth and defensive businesses amid a sharp global wobble in artificial-intelligence-linked shares. Halma underperformed during recent sessions, with its shares falling around 5% on 15 October in a weak patch for selected premium-valued growth stocks. That makes …

Ankur Sharma | 16 October 2026

Smith & Nephew Shares: Surgical Recovery and Product Execution Shape LSE:SN. Outlook

• Smith & Nephew is followed as a medical-technology company whose results depend on procedure volumes, surgeon adoption, product launches and operational execution. Demand for orthopaedic and sports-medicine products can be influenced by hospital capacity, elective-surgery backlogs and healthcare budgets. Investors are also interested …

Ankur Sharma | 16 October 2026

Why Did Fusion Antibodies (LSE:FAB) Shares Tumble After Its AGM Trading Update?

Shares in Fusion Antibodies (LSE:FAB) fell sharply on 15 October 2026 after the company published its AGM statement, including an H1 trading and R&D update, at 07:00 ahead of its annual general meeting. The update showed that unaudited revenue for the first half of …

Ankur Sharma | 16 October 2026
Support

Hi! How can we help you today?

Loading…